PTPI's Business Model
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
| Sector & Industry | Healthcare / Drug Manufacturers - Specialty & Generic |
| Website | https://www.petrospharma.com |
| CEO (Chief Executive Officer) | Fady Boctor |
| Number of Employees | |
| IPO date | December 2, 2020 |
PTPI Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 1185 Avenue of the Americas |
| City | New York City |
| State | NY |
| Phone | 973-242-0005 |
| Zip Code | 10036 |
| Other Identifiers | |
| CIK | 0001815903 |
| ISIN | US71678J3086 |
| CUSIP | 71678J308 |
| Open | 0.0356 |
| Previous Close | 0.0335 |
| Volume | 141.4 Thou. |
| Average Volume | 11.37 Mil. |
| Day’s Range | 0.0325 – 0.0356 |
| 52 Week Range | 0.023-16.25 |
| MA (50) | 0.18454 |
| MA (200) | 4.78601 |
| Market Cap | 1.01 Mil. |
| Shares Out. | 31.16 Mil. |
| Earnings Date | Sep 03, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
